IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja®/Fetcroja® (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory Infections
October 21, 2026 · 8:00 AM · OSAKA, Japan
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) will present new data at IDWeek 2026 that reinforce the role of Fetroja®/Fetcroja® (cefiderocol), an innovative siderophore cephalosporin, in serious Gram-negative infections. Cefiderocol data highlights at IDWeek will include new U.S. real-world data demonstrating improved clinical outcomes with early cefiderocol treatment versus salvage ther...
- PublishedOctober 21, 2026 · 8:00 AM
- LocationOSAKA, Japan
- IndustryScience
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →